Chemotherapy Effect
222
52
61
73
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Research Maturity
73 completed trials (33% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.8%
4 terminated out of 222 trials
94.8%
+8.3% vs benchmark
12%
27 trials in Phase 3/4
7%
5 of 73 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 73 completed trials
Clinical Trials (222)
Physical Capacity in Hodgkin Lymphoma Survivors
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
Massage Impact on Sleep in Pediatric Oncology
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
TME Alteration in HER2 Positive Breast Cancer
Photobiomodulation in the Prevention and Management of Oral Mucositis in Children
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
Neoadjuvant Treatment Modalities in Esophageal Cancer
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Effects of Virtual Museum Visit on Pain, Fatigue, and Anxiety in Patients Receiving Chemotherapy
Anxiolytic Effects of Socio-aesthetics in Cancer Patients Undergoing Chemotherapy
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Improve Cancer-related Cognitive Impairment
The Effect of Sujok Therapy on Patient Comfort, Pain Intensity, and Anxiety Level in Cancer Patients With Port Catheter Placement
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy